A Phase III, Randomized, Controlled, Multi-centre, 3-Arm Study of NeoadjuvantOsimertinib as Monotherapy or in Combination with Chemotherapy versus Standard ofCare Chemotherapy Alone for the Treatment of Patients with Epidermal Growth FactorReceptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
Sponsor: |
AstraZeneca |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5068 |
U.S. Govt. ID: |
NCT04351555 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to see whether the medication osimertinib (TAGRISSOTM) alone or when used in combination with chemotherapy is more effective than chemotherapy alone for the treatment of early stage Non-Small Cell Lung Cancer prior to surgery. Osimertinib is an EGFR TKI therapy that targets EGFR mutations. When a tumor is found to have this type of mutation, there is a class of drugs known as EGFR tyrosine kinase inhibitors (TKIs) which target the mutation to treat the patient.
This study is closed
Investigator
Catherine Shu, MD
Are you at least 18 years old? |
Yes |
No |
Do you have Non-Small Cell Lung Cancer, that is able to be removed? |
Yes |
No |
Do you have a life expectancy of greater than 6 months? |
Yes |
No |
Do you have a history of organ transplantation? |
Yes |
No |